6505--Radiopharmaceutical PLUVICTO

Awarded Limited / Sole Source Justification Posted

Solicitation number
36C24826Q0189
Agency
Set-aside
No set-aside

Opportunity facts

Contract number
36F79720D0180-36C24826F0082 Federal contract award

Notice details come from SAM.gov. Updated .

About this opportunity

The Department of Veterans Affairs, Veterans Integrated Service Network 8 (Caribbean Healthcare System, Network Contracting Office 8 in San Juan, Puerto Rico) issued a sole source justification notice for the procurement of 138 doses of Pluvicto, a specialized radiopharmaceutical therapy used to treat metastatic castration-resistant prostate cancer. The justification for sole source procurement is based on the fact that Pluvicto is manufactured exclusively by Advanced Accelerator Applications and distributed solely by Novartis Pharmaceuticals Corporation, with no viable alternative sources available due to patent protections and proprietary limitations. Novartis Pharmaceuticals Corporation, located at 59 Route 10, East Hanover, New Jersey, was awarded the contract (number 36F79720D0180) on February 24, 2026, with a total award value of $4,732,607.88 and a base contract term of six months. The procurement was authorized under the General Services Administration Federal Supply Schedule program, and extensive market research across multiple federal databases confirmed no substitute products or alternative vendors were available to meet the government's requirements.

Notice text

See attached Justification PDF. Awarded contract 36F79720D0180 to NOVARTIS PHARMACEUTICALS CORPORATION for 4732607.88000000 on 2026-02-24.

Files

File Type Posted
36C248-26-AP-1448 LSJ Pluvicto_Redacted.pdf PDF
36F79720D0180 36C24826F0082_1.pdf PDF

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity